Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apyx Medical (APYX) Enterprise Value (2016 - 2026)

Apyx Medical filings provide 16 years of Enterprise Value readings, the most recent being -$31.4 million for Q4 2025.

  • On a quarterly basis, Enterprise Value rose 0.65% to -$31.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$31.4 million, a 0.65% increase, with the full-year FY2025 number at -$31.4 million, up 0.65% from a year prior.
  • Enterprise Value hit -$31.4 million in Q4 2025 for Apyx Medical, down from -$24.9 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$10.0 million in Q4 2022 to a low of -$43.4 million in Q4 2023.
  • Median Enterprise Value over the past 5 years was -$29.8 million (2021), compared with a mean of -$27.5 million.
  • Biggest five-year swings in Enterprise Value: surged 67.36% in 2022 and later plummeted 335.49% in 2023.
  • Apyx Medical's Enterprise Value stood at -$30.6 million in 2021, then surged by 67.36% to -$10.0 million in 2022, then crashed by 335.49% to -$43.4 million in 2023, then grew by 27.2% to -$31.6 million in 2024, then rose by 0.65% to -$31.4 million in 2025.
  • The last three reported values for Enterprise Value were -$31.4 million (Q4 2025), -$24.9 million (Q3 2025), and -$29.1 million (Q2 2025) per Business Quant data.